

Curriculum Vitae

Name: Tatsuya Yamashita, MD, PhD

Current Position, Department, Affiliation:

Associate Professor,

Advanced preventive medical sciences research center, Kanazawa University, Japan

Department of Gastroenterology, Kanazawa University Hospital, Japan

Director, WHO Collaborating Center for Chronic Hepatitis and Liver Cancer, Kanazawa University,
Japan

Area of interest:

1. Diagnosis and Treatment of Hepatocellular carcinoma
2. Diagnosis and Treatment of Viral Hepatitis

Education:

1993 Graduate from Kanazawa University School of Medicine (MD)

1998 Graduate from Graduate School of Medicine, Kanazawa University (PhD)

Career Experiences:

January 1 2018~Now

Associate Professor, Advanced preventive medical sciences research center, Kanazawa University

April 1 2016~December 31 2017

Lecture, Department of Gastroenterology, Kanazawa University Hospital

April 1 2009~March 2016

Research Professor, Center for Education in Community Medicine (Department of Community
Medicine and Medical Education), Kanazawa University Hospital

June 1 2014~November 30 2014

Secondment, Global Hepatitis Programme, Department of HIV, World Health Organization

April 1 2001~July 31 2009

Assistant Professor, Department of Gastroenterology, Kanazawa University Hospital

October 1 1999~March 31 2001

Medical staff, Department of Gastroenterology, Kanazawa University Hospital

Professional Memberships (Selected):

American Society of Clinical Oncology, Japanese Society of Medical Oncology, Japan Society of
Clinical Oncology, Japanese Cancer Association, Liver Cancer Study Group of Japan, Japan
Association of Molecular Targeted Therapy for HCC, The Japanese Society of Gastroenterology, The

Japan Society of Hepatology, The Japanese Society of Internal Medicine, Japan Gastroenterological Endoscopy Society, The Japan Society of Ultrasonics in Medicine, The Japan Society of Ultrasonics in Medicine, Japanese Society of Implantable Port Assisted Treatment

Professional roles:

- Special member of committee for revised Japanese Clinical Guidelines for Hepatocellular carcinoma in The Japan Society of Hepatology
- Member of clinical practice guidelines for cancers (field of liver cancer) in Japan Society of Clinical Oncology
- Member of Editorial Board for Liver Cancer
-

Clinical trials

(I attended to the following clinical trials as Principle Investigator in our institute)

1. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002), NCT03713593
2. Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC, NCT03412773
3. A Study of Nivolumab in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (CheckMate 9DX), NCT03383458
4. Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240), NCT02702401
5. An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma, NCT02576509
6. A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2), NCT02435433
7. A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC) (JET-HCC), NCT02029157
8. A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma, NCT01761266